Citations

Mayo Clinic

Showing 10 of 108523 citations.

Adherence to a pedometer‐based physical activity intervention following kidney transplant and impact on metabolic parameters
Lorenz, Elizabeth C. , Amer, Hatem , Dean, Patrick G. , Stegall, Mark D. , Cosio, Fernando G., Cheville, Andrea , Stegall, Mark D , Amer, Hatem

Clinical Transplantation | April 2, 2015 | Volume: 29 | Issue: 6 | Pages: 560-568

10.1111/ctr.12553 | PMID 25845820 Get It

AbstractThe majority of kidney transplant recipients die from cardiovascular events. Physical activity may be a modifiable risk factor for cardiovascular disease following transplant. The goal of our study was to examine adherence to a physical activity intervention following kidney transplant and its impact on metabolic parameters. All patients who received a kidney transplant at our center between 12/2010 and 12/2011 received usual care (n = 162), while patients transplanted between 12/2011 and 1/2013 received a 90‐day pedometer‐based physical activity intervention (n = 145). Metabolic parameters were assessed at four and 12 months post‐transplant. Baseline demographics and clinical management were similar between cohorts. Adherence to the prescription was 36.5%. Patients in the physical activity cohort had lower systolic and diastolic blood pressure four months post‐transplant compared to the usual care cohort (122 ± 18 vs. 126 ± 16 mmHg, p = 0.049 and 73 ± 10 vs. 77 ± 9, p = 0.004) and less impaired fasting glucose (20.7% vs. 30.9%, p = 0.04). Twelve‐month outcomes were not different between cohorts. Over one‐third of our cohort adhered to a pedometer‐based physical activity intervention following kidney transplant, and the intervention was associated with improved metabolic parameters. Further study of post‐transplant exercise interventions and methods to optimize long‐term adherence are needed.
The Inflammatory Hypothesis of Atrial Fibrillation: Diagnostic Marker, Therapeutic Target, or Innocent Bystander?
Witt, Chance M. , Witt, Chance, Kapa, Suraj

Journal of Cardiovascular Electrophysiology | April 2, 2015 | Volume: 26 | Issue: 6 | Pages: 641-643

10.1111/jce.12680 | PMID 25845673 Get It

ANMS‐ESNM position paper and consensus guidelines on biofeedback therapy for anorectal disorders
Benninga, Marc A. , Bharucha, Adil E. , Chiarioni, Giuseppe , Lorenzo, Carlo Di , Whitehead, William E. , Rao, Satish S.C.

Neurogastroenterology & Motility | April 2, 2015 | Volume: 27 | Issue: 5 | Pages: 594-609

10.1111/nmo.12520 | PMID 25828100 Get It

AbstractBackgroundAnorectal disorders such as dyssynergic defecation, fecal incontinence, levator ani syndrome, and solitary rectal ulcer syndrome are common, and affect both the adult and pediatric populations. Although they are treated with several treatment approaches, over the last two decades, biofeedback therapy using visual and verbal feedback techniques has emerged as an useful option. Because it is safe, it is commonly recommended. However, the clinical efficacy of biofeedback therapy in adults and children is not clearly known, and there is a lack of critical appraisal of the techniques used and the outcomes of biofeedback therapy for these disorders.PurposeThe American Neurogastroenterology and Motility Society and the European Society of Neurogastroenterology and Motility convened a task force to examine the indications, study performance characteristics, methodologies used, and the efficacy of biofeedback therapy, and to provide evidence‐based recommendations. Based on the strength of evidence, biofeedback therapy is recommended for the short‐term and long‐term treatment of constipation with dyssynergic defecation (Level I, Grade A), and for the treatment of fecal incontinence (Level II, Grade B). Biofeedback therapy may be useful in the short‐term treatment of Levator Ani Syndrome with dyssynergic defecation (Level II, Grade B), and solitary rectal ulcer syndrome with dyssynergic defecation (Level III, Grade C), but the evidence is fair. Evidence does not support the use of biofeedback for the treatment of childhood constipation (Level 1, Grade D).
Effect of Unblinding on Participants' Perceptions of Risk and Confidence in a Large Double-Blind Clinical Trial of Chemotherapy for Breast Cancer
Sepucha, Karen , O’Neill, Anne, Motley, Christine, Swaby, Ramona F., Schneider, Bryan P. , Dang, Chau T. , Northfelt, Donald W. , Partridge, Ann H. , Miller, Kathy D. , Sledge, George W.

JAMA Oncology | April 2, 2015 | Volume: 1 | Issue: 3 | Pages: 369

10.1001/jamaoncol.2015.0246 | PMID 26114161 Get It

Hypomagnesaemia linked to depression: a systematic review and meta‐analysis
Cheungpasitporn, Wisit , Srivali, Narat , Ungprasert, Patompong , Varothai, Narittaya, Sanguankeo, Anawin , Kittanamongkolchai, Wonngarm , Erickson, Stephen B., Thongprayoon, Charat , Mao, Michael A. , Cheungpasitporn, Wisit , Srivali, Narat

Internal Medicine Journal | April 2, 2015 | Volume: 45 | Issue: 4 | Pages: 436-440

10.1111/imj.12682 | PMID 25827510 Get It

AbstractBackgroundThe reported risk of depression in patients with hypomagnesaemia is controversial.AimThe objective of this meta‐analysis was to assess the association between depression and hypomagnesaemia.MethodsA literature search was performed using MEDLINE, EMBASE, Cochrane Database and clinicaltrials.gov from inception through October 2014. Studies that reported odds ratios, relative risks or hazard ratios comparing the risk of depression in patients with hypomagnesaemia were included. Pooled risk ratios (RR) and 95% confidence interval (CI) were calculated using a random‐effect, generic inverse variance method.ResultsSix observational studies (three cohort studies, two cross‐sectional studies and a case–control study) with a total of 19 137 patients were identified and included in the data analysis. The pooled RR of depression in patients with hypomagnesaemia was 1.34 (95% CI, 1.01–1.79, I2 = 33%). The association between depression and hypomagnesaemia was marginally insignificant after the sensitivity analysis including only cohort and case–control studies, with a pooled RR of 1.38 (95% CI, 0.92–2.07, I2 = 24%).ConclusionOur study demonstrates a potential association between hypomagnesaemia and depression. Further studies assessing the benefits of treatment of hypomagnesaemia in patients with depression are needed.
Repair of Osteochondral Defects in the Minipig Model by Opf Hydrogel Loaded with Adipose-Derived Mesenchymal Stem Cells
Girolamo, Laura de , Niada, Stefania , Arrigoni, E. , Giancamillo, Alessia Di , Domeneghini, C. , Dadsetan, Mahrokh, Yaszemski, Michael J. , Gastaldi, Dario , Vena, Pasquale , Taffetani, Matteo , Zerbi, Alberto , Sansone, Valerio , Peretti, Giuseppe M. , Brini, A.T.

Regenerative Medicine | April 2, 2015 | Volume: 10 | Issue: 2 | Pages: 135-151

10.2217/rme.14.77 | PMID 25835479 Get It

Impairments and comorbidities of polyneuropathy revealed by population-based analyses
Hoffman, E. Matthew , Staff, Nathan P. , Robb, Jared M., Sauver, Jennifer L. St. , Dyck, P. James B. , Klein, Christopher J. , St Sauver, Jennifer L, Staff, Nathan P , Klein, Christopher J , St Sauver, Jennifer L

Neurology | April 2, 2015 | Volume: 84 | Issue: 16 | Pages: 1644-1651

10.1212/wnl.0000000000001492 | PMID 25832668 Get It

Double Chambered Right Ventricle with Ventricular Septal Defect in Adults: Case Series and Review of the Literature
Moustafa, Sherif, Patton, David J., Alvarez, Nanette, Shanawani, Mansour Al, AlDossari, Khalid, Connelly, Michael S. , Prieur, Timothy, Mookadam, Farouk

Journal of Cardiovascular Ultrasound | April 2, 2015 | Volume: 23 | Issue: 1 | Pages: 48

10.4250/jcu.2015.23.1.48 | PMID 25883758 Get It

Care in the Last Year of Life for Community Patients With Heart Failure
Redfield, Margaret M. , Jiang, Ruoxiang , Weston, Susan A., Roger, Véronique L. , Dunlay, Shannon M.

Circulation: Heart Failure | April 2, 2015 | Volume: 8 | Issue: 3 | Pages: 489-496

10.1161/circheartfailure.114.001826 | PMID 25834184 Get It

Background— Healthcare utilization peaks at the end of life (EOL) in patients with heart failure. However, it is unclear what factors affect end of life utilization in patients with heart failure and if utilization has changed over time. Methods and Results— Southeastern Minnesota residents with heart failure were prospectively enrolled into a longitudinal cohort study from 2003 to 2011. Patients who died before December 31, 2012, were included in the analysis. Information on hospitalizations and outpatient visits in the last year of life was obtained using administrative sources. Negative binomial regression was used to assess the association between patient characteristics and utilization. The 698 decedents (47.3% men; 53.4% preserved ejection fraction) experienced 1528 hospitalizations (median 2 per person; range, 0–12; 37.6% because of cardiovascular causes) and 12 927 outpatient visits (median 14 per person; range, 0–119) in their last year of life. Most patients (81.5%) were hospitalized at least once and 28.4% died in the hospital. Patients who were older and those with dementia had lower utilization. Patients who were married, resided in a skilled nursing facility, and had more comorbidities had higher utilization. Patients with preserved ejection fraction had higher rates of noncardiovascular hospitalizations although other utilization was similar. Over time, rates of hospitalizations and outpatient visits decreased, whereas palliative care consults and enrollment in hospice increased. Conclusions— Although patient factors remain associated with differential healthcare utilization at the end of life, utilization declined over time and use of palliative care services increased. These results are encouraging given the high resource use in patients with heart failure.
The Investigational Proteasome Inhibitor Ixazomib for the Treatment of Multiple Myeloma
Richardson, Paul G. , Moreau, Philippe , Laubach, Jacob P. , Gupta, Neeraj , Hui, Ai-Min, Miguel, Jesús F. San , Kumar, Shaji , Richardson, Paul Gerard Guy , Anderson, Kenneth C. , Gupta, Neeraj , Moreau, Philippe , San-Miguel, Jesus

Future Oncology | April 2, 2015 | Volume: 11 | Issue: 8 | Pages: 1153-1168

10.2217/fon.15.9 | PMID 25832873 Get It